Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 4.7 %

NASDAQ:BCLI opened at $1.21 on Monday. The firm’s fifty day simple moving average is $1.24 and its 200 day simple moving average is $1.62. The stock has a market cap of $7.89 million, a P/E ratio of -0.25 and a beta of 0.35. Brainstorm Cell Therapeutics has a twelve month low of $0.72 and a twelve month high of $10.05.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.